VERU Veru Inc: Return on Sales by Net Profit

Corporate emblem and logo of Veru Pharma (VERU)

Veru Inc. (VERU) is seeing a recovery in its reputational dynamics driven by new developments in endocrinology, while the return on sales remains at 0.00. Financial stability is constrained by revenue volatility across various segments. High R&D expenditures and stringent FDA oversight create significant barriers to entry. Analysis of the curve allows for an assessment of management efficiency and the timely identification of trend reversals.

Veru Inc. (VERU) - Company Sales Margin from 07/04/2022 to 11/19/2026

Analytical breakdowns and data insights for company Veru Inc. (VERU)

- share price and consensus valuation forecast:
Analysis of all company metrics:Veru, VERU
Flagship merchandise of Veru Corporation

An analysis of the credit quality of Veru Inc. (VERU) requires an assessment of the business's ability to generate net profit. Strong positions in oncology and women's health provide the company with fundamental stability. This level of commercial profitability shows the portion of income remaining after covering all operating and financial expenses. The indicator's trend reveals hidden risks regarding drug cost of goods sold. It is critical for investors to avoid purchases during metric stagnation, which foreshadows a potential drawdown.

Direct competitors

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|Net Profit Rate DCTH (Delcath Corp)|YMAB: Net Sales Margin|AURA - Company Sales Margin|CADL (Candel Therapeutics Inc.) - Net Sales Margin|Net Return on Sales ARAY (Accuray)|Return on Sales by Net Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Net Margin|Net Margin Citius Oncology, Inc. CTOR|HURA - Return on Sales by Net Profit|protaratx.com - Net Sales Margin|FATE - Net Sales Margin|WHWK: Net Sales Margin|TScan Therapeutics (TCRX) - Net Sales Margin|Net Margin Champions Oncology|Net Margin XBIT|Net Sales Margin CVM|Return on Sales by Net Profit OS Therapies Inc. OSTX|Net Margin Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Net Margin|ANL - Net Margin|Company Sales Margin Tempest Therapeutics TPST|XLO: Net Sales Margin|Enochian BioSciences (RENB) - Net Sales Margin|Return on Sales by Net Profit MURA|Kairos Pharma Ltd - Net Profit Margin|Net Sales Margin OKUR|CytoMed Therapeutics Limited (GDTC) - Net Profitability Margin|Net Sales Margin CRIS (Curis, Inc.)|APLM: Net Return on Sales|Tharimmune Corporation - Net Sales Margin|ADVB: Net Margin|GNPX: Net Sales Margin|CLDI (Calidi Biotherapeutics Inc.) - Net Margin|Net Margin Sunshine Biopharma, Inc.|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)